Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Have Suffered Losses Exceeding $50,000 In Eyepoint to contact him directly to discuss their options
NEW YORK, January 28, 2023 /PRNewswire/ — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against EyePoint Pharmaceuticals (“Eyepoint” or the “Company”) (NASDAQ: EYPT) .
If you have incurred losses exceeding $50,000 invest in Eyepoint stocks or options and want to discuss your legal rights, call partner Faruqi & Faruqi Josh Wilson directly at 877-247-4292 or 212-983-9330 (ext. 1310). You can also click here for more information: www.faruqilaw.com/EYPT.
There is no cost or obligation for you.
Faruqi & Faruqi is a leading national minority and women-owned securities law firm, with offices in New York, Pennsylvania, California and Georgia.
EyePoint Pharmaceuticals, Inc. operates as a biopharmaceutical company. The Company specializes in the development of drug devices to treat debilitating diseases of eye disorders and other chronic conditions. EyePoint Pharmaceuticals serves customers worldwide.
Lawyer advertisement. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Past results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated confidentially.
SOURCE Faruqi & Faruqi, LLP
